AMCASERTIB
Urologic Malignancies
Sumitomo Pharma America, Inc.Small moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
16 Active assets in the Urologic Malignancies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab Spanish Oncology Genito-Urinary Group | Phase 2 | B |
Tadalafil Regina Elena Cancer Institute | Phase 3 | B |
Atezolizumab British Columbia Cancer Agency | Phase 2 | B |
Ipilimumab Dana-Farber Cancer Institute | Phase 2 | B |
Riluzole University of California, Irvine | Phase 2 | CCC |
View all 31 →
Same molecule, other indications
AMCASERTIB is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →